Redeye continues to view Dignitana as very compelling long term growth case. The results in the Q3 did not show any real surprises. The positive outcome of the reimbursement levels in the US will drive growth in 2022 and forward. We adjust our near-term estimates and have increased our long-term growth estimates slightly. Consequently, we raise our fair value range to SEK 8 –28 per share with a base case of SEK 18 (16) per share.
LÄS MER
